These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9816193)
1. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Takimoto CH; Lu ZH; Zhang R; Liang MD; Larson LV; Cantilena LR; Grem JL; Allegra CJ; Diasio RB; Chu E Clin Cancer Res; 1996 Mar; 2(3):477-81. PubMed ID: 9816193 [TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Morrison GB; Bastian A; Dela Rosa T; Diasio RB; Takimoto CH Oncol Nurs Forum; 1997; 24(1):83-8. PubMed ID: 9007910 [TBL] [Abstract][Full Text] [Related]
3. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Lu Z; Zhang R; Diasio RB Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682 [TBL] [Abstract][Full Text] [Related]
4. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601 [TBL] [Abstract][Full Text] [Related]
6. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. Ogura K Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518 [TBL] [Abstract][Full Text] [Related]
7. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients]. Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669 [TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056 [TBL] [Abstract][Full Text] [Related]
9. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Milano G; Etienne MC Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962 [TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223 [TBL] [Abstract][Full Text] [Related]
12. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Kouwaki M; Hamajima N; Sumi S; Nonaka M; Sasaki M; Dobashi K; Kidouchi K; Togari H; Wada Y Clin Cancer Res; 1998 Dec; 4(12):2999-3004. PubMed ID: 9865912 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
15. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197 [TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. van Kuilenburg AB Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568 [TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. Amstutz U; Farese S; Aebi S; Largiadèr CR J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829 [TBL] [Abstract][Full Text] [Related]
18. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885 [TBL] [Abstract][Full Text] [Related]
19. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878 [TBL] [Abstract][Full Text] [Related]
20. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]